In 2022, OpenAI launched its first large-scale AI tool—an innovation that quickly reshaped how industries approached automation, creativity, and problem-solving. Since then, artificial intelligence has become part of everyday workflows, turning time-intensive tasks into faster, data-driven…
This Halloween, we made sure language barriers don’t haunt clinical research. 👻 We’re proud to facilitate more inclusive clinical trials by helping top sponsors and study teams communicate with participants in multiple languages—equipping them with the tools to reach the…
TrialX, in collaboration with investigators at the University of Iowa is proud to announce that the SAYSTOP Study App, developed to study antibiotic resistance using our remote data collection solution, has successfully completed enrollment. The “Study of…
The 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research (September 16–17, 2025, Philadelphia, PA) brought together senior clinical operations executives, patient advocates, and technology leaders to explore the future of clinical trials. AI, patient-centric trial…
ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects nerve cells controlling voluntary muscle movement. Each year, more than 5,000 people in the United States are diagnosed, and around 30,000 people are living…
Clinical Research Coordinators (CRCs) are often the first point of contact for participants, guiding them through every step of a study. From screening to consent management and recruitment to protocol compliance, CRCs handle a broad and…
Making clinical trials more diverse isn’t just the right thing to do — it’s essential for developing treatments that work for everyone. Yet, despite FDA guidance, many trials still fail to reflect the real-world diversity of…
